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Recent genome-wide association studies have identified multiple loci that are 
associated with an increased risk of developing coronary artery disease (CAD). 
The impact of these loci on the disease severity and prognosis of ischemic heart 
failure due to CAD is currently unknown. 
Methods 
We undertook association analysis of 7 single nucleotide polymorphism 
(rs599839, rs17465637, rs2972147, rs6922269, rs1333049, rs501120, and 
rs17228212) at 7 well established CAD risk loci (1p13.3, 1q41, 2q36.3, 6q25.1, 
9p21.3, 10q11.21, and 15q22.33, respectively) in 3,320 subjects diagnosed with 
systolic heart failure of ischemic aetiology and participating in the COntrolled 
ROsuvastatin multiNAtional Trial in Heart Failure (CORONA) trial. The 
primary outcome was the composite of time to first event of cardiovascular 
death, non-fatal myocardial infarction and non-fatal stroke, secondary 
outcomes included mortality and hospitalization due to worsening heart failure. 
Results 
None of the 7 loci were significantly associated with the primary composite 
endpoint of the CORONA trial (death from cardiovascular cases, nonfatal 
myocardial infarction, and nonfatal stroke). However, the 1p13.3 locus 
(rs599839) showed evidence for association with all-cause mortality (after 
adjustment for covariates; HR 0.74, 95%CI [0.61 to 0.90]; P=0.0025) and we 
confirmed the 1p13.3 locus (rs599839) to be associated with lipid parameters 
(total cholesterol (P=1.1x10
-4







Genetic variants strongly associated with CAD risk are not associated with the 
severity and outcome of ischemic heart failure. The observed association of the 
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Heart Failure (HF) is a highly prevalent condition affecting more than 15 
million patients in Europe alone and has a poor prognosis.
105
 In several familial 
forms of HF, disease-causing mutations have been identified including several 
mutations in genes coding for structural components of the sarcomere.
106,107
 For 
example, mutations in the genes encoding cardiac β-myosin heavy chain 
(MYH7) or cardiac myosin-binding protein C (MYBPC3) are known to cause 
hypertrophic and dilated cardiomyopathies.
108
 However, these Mendelian 
diseases only account for a small minority of all HF cases and only explain a 
minor proportion of the population attributable risk for HF. The vast majority 
of HF is a consequence of more complex genetic and environmental factors and 
the interactions among them. Coronary artery disease (CAD) is considered the 
major cause of HF. For the development of CAD, a number of genetic risk loci 
with common variants have recently been identified.
5-7
 The earliest findings 
derived from genome wide association studies were reported by the Wellcome 
Trust Case Control Consortium (WTCCC) and the German MI Family GWA 
studies, as well as the Coronary Artery Disease consortium, which together 
have identified 7 common variants that were robustly associated with CAD.
5,6
 
Whether these variants, with strong prior evidence to be associated 
with increased CAD risk, are also relevant for ischemic HF progression as 
reflected by HF severity and prognosis remains to be determined. In the present 
study, we have evaluated these 7 CAD risk loci in ischemic HF patients 
participating in the COntrolled ROsuvastatin multiNAtional study in heart 
failure (CORONA) and tested the hypothesis that the SNPs associated with 
CAD are also associated with ischemic HF disease severity and outcome. 
Methods 
The current study is a genetic sub-study of the CORONA trial. The CORONA 
trial aimed to determine the effect of rosuvastatin treatment on clinical outcome 
in patients with systolic heart failure from ischemic aetiology. The CORONA 
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study group is represented in the supplement. The CORONA trial has been 
published in detail, the main result was that rosuvastatin did not reduce the 
primary composite outcome of death from cardiovascular causes, nonfatal 





In- and exclusion criteria of the CORONA trial have been reported in detail 
previously.
109,110
 In brief, patients were 60 years of age or older, HF of ischemic 
aetiology, and a left ventricular ejection fraction (LVEF) of ≤ 40% with NYHA 
class III/IV symptoms or LVEF ≤ 35% with NYHA class II symptoms. Patients 
had to be clinically stable and on optimal treatment for at least 2 weeks before 
inclusion. Exclusion criteria included the following; recent myocardial 
infarction (MI) (<6 months); unstable angina or stroke within the past 3 
months; percutaneous coronary intervention (PCI) or coronary-artery bypass 
grafting (CABG); the implantation of a cardioverter defibrillator (ICD) or 
biventricular pacemaker within the past 3 months; heart transplantation; 
clinically significant/uncorrected primary valvular heart disease; hypertrophic 
cardiomyopathy; or systemic disease (e.g., amyloidosis). The CORONA trial 
included 5,011 patients,
110
 and DNA was obtained from 3,340 of them. We 
excluded 20 non-Caucasian subjects (8 black, 7 Asian, 5 ‘other’), leaving 3,320 
subjects for the current genetic sub-study of CORONA. The ethical committee 
at each of the participating hospitals approved this trial (see Supplemental 
Methods), and patients provided written informed consent.  
 
Definition of Phenotypes and outcome  
The severity of HF was assessed by LVEF and serum N-terminal pro B-type 
Natriuretic Peptide (NT-proBNP) levels. As one of the loci has also been 
identified in a GWAS for lipid traits, we specifically studied the association of 
this locus with available lipid traits. The primary outcome of the CORONA 
trial was the composite of death from cardiovascular cases, nonfatal myocardial 
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infarction, and nonfatal stroke, analysed according to the time to the first event. 
Secondary outcomes were death from any cause, any coronary event (defined 
as sudden death, fatal or nonfatal myocardial infarction, the performance of 
PCI or CABG, ventricular defibrillation by an ICD, resuscitation after cardiac 
arrest, or hospitalization for unstable angina), death from cardiovascular causes, 
sudden death, death from worsening heart failure, combination of mortality or 
worsening heart failure and athero-thrombotic endpoint. 
 
SNP selection and genotyping 
We studied 7 loci (1p13.3, 1q41, 2q36.3, 6q25.1, 9p21.3, 10q11.21, 15q22.33) 
which have been linked to CAD risk by previous GWAS.
5,6
 We genotyped the 
7 lead SNPs within these loci; rs599839, rs17465637, rs2972147, rs6922269, 
rs1333049, rs501120, and rs17228212 (Supplementary Table 1). Genotyping 
was carried out with TaqMan (Applied Biosystems) using standard protocols 
and was performed at the laboratory of AstraZeneca Pharmaceuticals (JCF), 
Alderley Park, UK without knowledge of clinical data. 
 
Statistical Analysis 
Normality of the data was determined by visual inspection. HsCRP and NT-
proBNP were non-normally distributed and therefore log-transformed. 
Genotypes were coded additively as 0, 1 or 2 in terms of the number of minor 
alleles. The baseline variables were analysed in linear model with only 
genotype as predictor and if significant, the following covariates were added to 
the adjusted model: age, sex, ejection fraction, NYHA class, systolic blood 
pressure, heart rate, body mass index, history of myocardial infarction, angina 
pectoris, diabetes mellitus, hypertension, stroke, intermittent claudication, 
aortic aneurysm, percutaneous coronary intervention, coronary artery bypass 
graft surgery, atrial fibrillation, implanted pacemaker, implanted cardiac 
defibrillator, smoking status, serum creatinine, alanine aminotransferase, 
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creatine kinase, thyroid-stimulating hormone, triglycerides, hsCRP and NT-
proBNP, as explained in detail by Wedel et al.
111
 HF outcome determinants 
were analysed using Cox regression of outcome versus number of minor 
alleles. Analyses were conducted unadjusted and after adjusted for the above 
mentioned co-variates. We considered a P-value <0.0071 for the primary 
endpoint statistically significant (Bonferroni adjustment of <0.05 for 7 
independent loci) and as suggestive for all secondary endpoint analyses. 
 
Results 
The baseline characteristics of the study population are presented in Table 1. 
The study population consisted of 3,320 HF patients with mean LVEF of 31% 
and a median NT-proBNP level of 151 pmol/L. There was a high prevalence of 
hypertension, diabetes mellitus, and chronic kidney disease in our population. 
Subjects were well treated for HF, with 87% using diuretics, 77% using beta-
blockers, 92% using ACE inhibitors or AT1-receptor antagonist, and 91% were 
treated with an antiplatelet agent or anticoagulant. The mean follow-up time 
was 2.73 years, accumulating 9,062 patient-years of follow-up. At baseline, 
1,986 patients (60%) had a history of MI, and 823 (25%) a history of CABG or 
PCI. Genotyping was successful in excess of 98% for all SNPs but one and the 
distributions of genotypes were consistent with the Hardy-Weinberg 
equilibrium as calculated using the chi-square test for deviation. Minor allele 
frequencies were similar in the current analyses compared to the discovery 
GWAS.
5,6





Table 1. Baseline characteristics of subjects in genetic sub-study of CORONA 
 n = 3,320 
Age (years) 72.3 ± 6.9 
Males n (%) 2530 (76.2) 
Left ventricular ejection fraction (%±SD) 31 ± 6.3 
NYHA class n (%)  
   II 1251 (37.7) 
   III 2035 (61.3) 
   IV 34 (1.0) 
History of n (%)  
   Angina Pectoris 2463 (74.2) 
   Aortic Aneurysm 84 (2.5) 
   Aortic Aneurysm Surgery Performed 47 (1.4) 
   Atrial Fibrillation/Flutter 1318 (39.7) 
   Diabetes Mellitus 933 (28.1) 
   Hypertension 2173 (65.5) 
   Implantable cardioverter-defibrillator 79 (2.4) 
   Implanted pacemaker 349 (10.5) 
   Intermitted claudication 392 (11.8) 
   Myocardial infarction 1986 (59.8) 
   Coronary Artery Bypass Surgery  537 (16.2) 
   Percutaneous Coronary Intervention  358 (10.8) 
   CABG or PCI 823 (24.8) 
   Stroke 386 (11.6) 
Smoking status n (%)  
   Non Smoker 1521 (45.8) 
   (Ex-)smoker 1797 (54.1) 
Heart Failure Medication at baseline n (%)  
   Loop diuretic 2421 (72.9) 
   Thiazide diuretic 776 (23.4) 
   Loop or Thiazide 2879 (86.7) 
   Beta-Blocker 2542 (76.6) 
   ACE inhibitor 2696 (81.2) 
   AT1-receptor blocker 428 (12.9) 
   ACE inhibitor or AT1-receptor blocker 3063 (92.3) 
   Aldosterone antagonist 1284 (38.7) 
   Digitalis 1072 (32.3) 
   Anti-platelet or Anti-coagulant 3020 (91.0) 
Blood pressure (mmHg)  
   Systolic 130.5 ± 16.1 
   Diastolic 77.0 ± 8.6 
Heart rate (beats/min) 71.2 ± 10.9 
BMI (kg/m
2
) 27.5 ± 4.4 
Serum creatinine (umol/L) 112.8 ± 26.5 
eGFR (ml/min/1.73m/m
2
BSA) 58.5 ± 14.0 
hs-CRP (mg/L) 3.3 (0.02-230) 
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Table 1 (continued). Baseline characteristics of subjects in genetic sub-study 
of CORONA 
NT-proBNP (pmol/L) 151 (1-3868) 
Lipids  
   Total cholesterol (mmol/L) 5.41 ± 1.07 
   LDL-cholesterol (mmol/L) 3.60 ± 0.94 
   HDL-cholesterol (mmol/L) 1.19 (0.47-3.55) 
   Apo-A1 (g/L) 1.51 ± 0.27 
   Apo-B (g/L) 1.28 ± 0.30 
   Apo-B / Apo-A (mean) 0.87 ± 0.24 
   Triglycerides (mmol/L) 1.68 (0.41-14.43) 
Abbreviations: NYHA = New York Heart Association; CABG = Coronary 
Artery Bypass Graft; PCI = Percutaneous Coronary Intervention; ACE = 
Acetylcholinesterase; AT1 = Angiotensin-1; BMI = body mass index; eGFR = 
estimated Glomerular Filtration Rate; hs-CRP = high sensitive C-reactive 
protein; NT-proBNP = N-terminal pro B-type natriuretic peptide, LDL = low-
density lipoprotein; HDL = high-density lipoprotein; Apo = apolipoprotein. 
Variables are expressed as mean (SD) when normally distributed and as median 




Table 2. CAD loci (P < 0.05) and heart failure disease markers in genetic sub-
study of CORONA 
  Locus SNP Model n 
Beta 
estimate 
LVEF 9p21.3 rs1333049 Unadj. 3,300 0.0044 
   Adj.
a 
2,212 0.0038 
 10q11.21 rs501120 Unadj. 3,300 0.0054 
   Adj.
a
 2,216 0.0022 
 15q22.33 rs17228212 Unadj. 3,303 -0.005 
   Adj.
a
 2,218 -0.0031 
log NT-proBNP 
(pmol/L) 
10q11.21 rs501120 Unadj. 2,412 -0.11 
   Adj.
a
 2,216 -0.064 
BMI (kg/m2) 1q41 rs17465637 Unadj. 3,298 0.35 
   Adj.
a
 2,220 0.3 
Serum creatinine 
(umol/L) 
10q11.21 rs501120 Unadj. 3,300 -2.01 
      Adj.
a
 2,216 -0.43 
Abbreviations: SNP = single nucleotide polymorphism; LVEF = left ventricular 
ejection fraction; BMI = body mass index; NT-proBNP = N-terminal pro B-
type natriuretic peptide. 
a
Adjusted analyses were adjusted for age, sex, ejection 
fraction, NYHA class, systolic blood pressure, heart rate, body mass index, 
history of myocardial infarction, angina pectoris, diabetes mellitus, 
hypertension, stroke, intermittent claudication, aortic aneurysm, percutaneous 
coronary intervention, coronary artery bypass graft surgery, atrial fibrillation, 
implanted pacemaker, implanted cardiac defibrillator, smoking status, serum 
creatinine, alanine aminotransferase, creatine kinase, thyroid-stimulating 
hormone, triglycerides, hsCRP and NT-proBNP.
111
 As some covariates were 
also baseline variables or strongly associated to a baseline variable, covariates 
were excluded from analyses (see Supplementary Table 2). Results of all 




Table 2 (continued). CAD loci (P < 0.05) and heart failure disease markers in 




Excluded from adjusted 
analysis 
0.0015 - 0.0074 3.6×10
-3
 LVEF 
0.0005 - 0.0071 2.3×10
-2
  
0.0012 - 0.0097 1.2×10
-2
  
-0.0025 - 0.0068 0.36  
-0.0084 - -0.0016 4.0×10
-3
  
-0.0069 - 0.0008 0.12  
-0.20 - -0.01 2.7×10
-2
 
log NT-proBNP (pmol/L) 
 
-0.14 - 0.02 0.12  
0.11 - 0.60 4.8×10
-3
 BMI (kg/m2) 
0.03 - 0.58 2.9×10
-2
  
-3.80 - -0.21 2.8×10
-2
 
Serum creatinine (umol/L) 
 






CAD loci and HF disease severity; LVEF and NT-proBNP  
LVEF and NT-proBNP were taken as indicators of HF disease severity and 
their association with the 7 genetic loci was determined. Although some of the 
unadjusted association P-values were smaller than 0.05 (Table 2), we 
considered none of these loci associated with LVEF or NT-proBNP considering 
the multiple testing burden of these secondary endpoints. 
 
Prognostic value of CAD loci for cardiovascular events and 
disease progression in HF 
Next, we tested the association between the CAD-associated loci with HF 
disease outcome. None of the 7 loci predicted the occurrence of the primary 
endpoint (composite endpoint of cardiovascular mortality, non-fatal myocardial 
infarction or non-fatal stroke, analysed as time to first event) or death caused by 
cardiovascular events. When the individual components of the primary 
endpoint were considered, we observed that the 1p13.3 (rs599839) locus, 
showed a borderline association with all-cause mortality (HR 0.86, 95%CI 
[0.74-1.00], P=0.499) which became somewhat stronger after adjustment for 
covariates (HR 0.74, [0.61-0.90], P=0.0025). Using ordered Jonckheere-
Terpstra test, the 1p13.3 locus also showed association with the total number of 
hospitalizations due to cardiovascular causes (P=0.0093) and the 10q11.21 
locus showed an association with the number of hospitalizations due to 
worsening HF. All associations with P<0.05 are presented in Table 3 (all 





Associations of CAD loci with lipid profile in HF 
The 7 loci were evaluated for association with the available serum lipid profile 
parameters. After adjustments, the 1p13.3 locus (rs599839) was associated with 
total cholesterol (P=1.1×10
-4
), low-density-lipoprotein (LDL) cholesterol 
(P=3.5×10
-7
), serum Apolipoprotein-B (Apo-B) levels (P=5.1×10
-8
) and the 
Apo-B/Apo-A1 ratio (P=8.0×10
-9
). Associations with lipid parameters with P-
values smaller than 0.05 are presented in Table 4 (all associations are presented 




Table 3. CAD loci (P < 0.05) and prognosis of ischemic heart failure in genetic 
sub-study of CORONA 
  Locus SNP Model 
All-cause mortality 1p13.3 rs599839 Unadj. 
   Adj.
a
 





   Adj.
a
 
    
Number of hospitalizations 





Number of hospitalizations 







Abbreviations: SNP = single nucleotide polymorphism; WHF = worsening 
heart failure. 
a
Adjusted analyses were adjusted for age, sex, ejection fraction, 
NYHA class, systolic blood pressure, heart rate, body mass index, history of 
myocardial infarction, angina pectoris, diabetes mellitus, hypertension, stroke, 
intermittent claudication, aortic aneurysm, percutaneous coronary intervention, 
coronary artery bypass graft surgery, atrial fibrillation, implanted pacemaker, 
implanted cardiac defibrillator, smoking status, serum creatinine, alanine 
aminotransferase, creatine kinase, thyroid-stimulating hormone, triglycerides, 
hsCRP and NT-proBNP.
111
 * directions were concordant with previous 
observations.
6





Table 3 (continued). CAD loci (P < 0.05) and prognosis of ischemic heart 
failure in genetic sub-study of CORONA 






3,300 527 0.86* 0.74-1.00 4.99×10
-2
 
2,218 341 0.74* 0.61-0.90 2.5×10
-3
 
3,300 1046 0.85* 0.75-0.97 1.2×10
-2
 
2,216 670 0.82* 0.70-0.96 1.5×10
-2
 
    
 
 












Table 4. CAD loci (P < 0.05) and lipid characteristics in genetic sub-study of 
CORONA 
  Locus SNP Model n 
Total cholestorol (mmol/L) 1p13.3 rs599839 Unadj. 3,285 
   Adj.
a
 2,219 
 10q11.21 rs501120 Unadj. 3,285 
   Adj.
a
 2,217 
LDL cholesterol (mmol/L) 1p13.3 rs599839 Unadj. 3,285 
   Adj.
a
 2,219 
 10q11.21 rs501120 Unadj. 3,285 
   Adj.
a
 2,217 
Triglycerides (mmol/L) 1p13.3 rs599839 Unadj. 3,285 
   Adj.
a
 2,219 
 9p21.3 rs1333049 Unadj. 3,285 
   Adj.
a
 2,213 
Apo-B (g/L) 1p13.3 rs599839 Unadj. 3,264 
   Adj.
a
 2,218 
 10q11.21 rs501120 Unadj. 3,267 
   Adj.
a
 2,216 
Apo-B / Apo-A1 ratio 1p13.3 rs599839 Unadj. 3,264 
      Adj.
a
 2,218 
Abbreviations: SNP = single nucleotide polymorphism; LDL = low-density-
lipoprotein; HDL = high-density-lipoprotein; Apo-B = apolipoprotein-B; Apo-
A1 = apolipoprotein-A1.
 a
Adjusted analyses were adjusted for age, sex, ejection 
fraction, NYHA class, systolic blood pressure, heart rate, body mass index, 
history of myocardial infarction, angina pectoris, diabetes mellitus, 
hypertension, stroke, intermittent claudication, aortic aneurysm, percutaneous 
coronary intervention, coronary artery bypass graft surgery, atrial fibrillation, 
implanted pacemaker, implanted cardiac defibrillator, smoking status, serum 
creatinine, alanine aminotransferase, creatine kinase, thyroid-stimulating 
hormone, triglycerides, hsCRP and NT-proBNP.
111
 As some covariates were 
also baseline variables or strongly associated to a baseline variable, covariates 
were excluded from analysis (see Supplementary Table 2). Data for all SNPs 





Table 4 (continued). CAD loci (P < 0.05) and lipid characteristics in genetic 
sub-study of CORONA 
Beta estimate 95%CI P value 
-0.14 -0.20 - -0.08 1.2×10
-5
 
-0.14 -0.21 - -0.07 1.1×10
-4
 
-0.07 -0.15 - -0.001 4.7×10
-2
 
-0.05 -0.13 - 0.03 0.24 
-0.16 -0.22 - -0.11 1.8×10
-9
 
-0.17 -0.23 - -0.1 3.5×10
-7
 
-0.07 -0.13 - -0.004 3.6×10
-2
 
-0.05 -0.12 - 0.02 0.19 
0.08 0.007 - 0.15 3.2×10
-2
 
0.07 -0.005 - 0.15 6.6×10
-2
 
-0.08 -0.14 - -0.02 7.0×10
-3
 
-0.06 -0.13 - 0.001 5.4×10
-2
 
-0.06 -0.07 - -0.04 2.2×10
-10
 
-0.06 -0.08 - -0.04 5.1×10
-8
 
-0.02 -0.04 - -0.002 2.8×10
-2
 
-0.02 -0.05 - 0.002 7.5×10
-2
 
-0.05 -0.06 - -0.03 3.3×10
-11
 







HF is a common condition in which cardiac function is affected, leading to a 
variety of symptoms like dyspnoea, fatigue, and fluid retention. The most 
frequent cause of HF is CAD. In the past few years, several genetic variants 
have been associated with CAD resulting in new insight in the pathophysiology 
of CAD.
5
 We tested the hypothesis that the presence of variants associated with 
prevalent CAD is also causally linked to increased severity of HF and worse 
prognosis. Our findings lend little support to this hypothesis. Since this was a 
candidate analyses, the observed associations are suggestive and require further 
replication. 
 
The loci we evaluated included the 9p21 locus, which is considered the most 
robust common genetic risk factor for CAD with the rs1333049 variant 
showing the strongest signal for association with CAD in WTCCC and German 
studies.
5
 This locus harbours a large non-coding transcript of unknown 
function, designated the name CDKN2B antisense RNA (CDKN2BAS or 
ANRIL). This locus is related to atherosclerotic disease burden in different 
vascular beds
112
 and deletion of ANRIL in human aortic smooth muscle cells 
leads to a increase in proliferative capacity in culture.
113
 Furthermore, the rate 
of proliferation of vascular smooth muscle cells is attenuated by the 9p21 
genotype and the CAD risk allele (C allele) increases vascular smooth muscle 
cell proliferation, thereby likely playing an important role in the development 
of atherosclerosis.
114
 Despite these findings, the presence of this genetic 
variant, and presumably increased atherosclerotic burden, did not translate into 
increased HF severity or worse outcome in patients with ischemic HF in the 
present study. A possible explanation is that the effect of this locus acting 
through increased atherosclerotic disease burden is confounded by events 
defined by the severity of heart failure. In addition, the vulnerability to develop 
HF given a similar atherosclerotic disease burden might also differ among 
patients and could be a consequence of complex gene-environment interactions. 
107 
 
The presence or absence of concomitant conditions and diseases including 
diabetes, renal dysfunction, or pulmonary disease may also modify the 
phenotype. Furthermore, patients in our study were well treated with beta-
blockers, angiotensin-converting-enzyme inhibitors, and aldosterone 
antagonists, which might further have decreased the differences between 
patients due to genetic risk factors. Also related to optimisation of 
pharmacotherapy, Wedel et al. calculated specifically for the CORONA trial, 
that the proportionate contribution of myocardial infarction to total mortality, 
related to the atherosclerotic disease burden, was relatively small. The Wald 
statistic of myocardial infarction for total mortality was 3.9, while for example 
log NT-proBNP showed a Wald statistic for total mortality of 167.
111
 This 
suggests that the pathological role of genetic risk variants acting through CAD 
might also be relatively small, and could therefore have remained undetected in 
our study. Nevertheless, the current sample size of systematically collected 
ischemic HF patients with DNA available to perform genotyping studies is the 
largest available in the world to date and it will be difficult, if not impossible, 
to extend the sample size within reasonable timeframes. The results of this 




Considering prior knowledge, we also studied the association of the genotyped 
genetic variants with lipid parameters.
115-117
 We were able to confirm previous 
reported associations between the 1p13.3 locus (rs599839) and lipids. We also 
provided novel data on this locus and its association with apolipoproteins. The 
1p13.3 locus was most strongly associated with Apo-B levels (stronger than the 
known LDL association), suggesting Apo-B is a candidate effector molecule. 
The genomic region at 1p13.3 encodes 4 genes: proline/serine-rich coiled 
protein 1 (PSRC1), cadherin EGF LAG sevenpass G-type receptor 2 (CELSR2), 
myosin-binding protein H-like (MYBHL), and sortilin 1 (SORT1). Recent 
studies have revealed a role for SORT1 in Apo-B secretion and LDL 
catabolism: overexpression of SORT1 resulted in increased serum LDL and 





 In our secondary analyses we 
observed an association with all-cause mortality and the number of 
hospitalizations due to cardiovascular causes for the 1p13.3 locus. As these 
were secondary analyses, which would not survive strict adjustment for 
multiple testing, the interpretation of these findings should be cautious as they 
require further confirmation. In addition, the explanation and possible relation 
to lower cholesterol and apolipoprotein levels cannot be deducted from the 
current study. 
 
Among the strengths of the present study are the size and quality of the study 
cohort, which is the largest heart failure cohorts with DNA available to date. 
Patient characteristics and outcomes have been collected and documented 
systematically within the framework of a clinical trial. However, there are some 
limitations which we need to address. At first, we have limited the variants 
tested to the N.J. Samani paper published in 2007
5
 and the variants reported by 
the Coronary Artery Disease Consortium in 2009.
6
 Recent GWA studies have 
identified additional variants involved in CAD development. The recent 
publication by the CARDIoGRAMplusC4D consortium reported 46 genetic 
variants associated with CAD risk.
120
 We cannot exclude that there might be 
variants among these 46 that are related to heart failure outcomes and this 
remains an objective for further study. We performed a post-hoc power 
calculation to consider the possibility that our study might have lacked 
power.
121
 Assuming an effect size of the risk variant comparable to the CAD 
discovery GWAS (genotype relative risk Aa = 1.3; genotype relative risk AA = 
1.6),
5,6
 we calculated the power to detect a significant effect for a variant 
(prevalence cases = 0.175; number of cases = 581; control:case ratio = 4.7). 
The power of our analyses ranged from 0.90 to 0.91 depending on the 
frequency of the risk allele (ranging from 0.25 to 0.55). Future studies with 
larger sample sizes, containing all CAD loci, are warranted to further evaluate 





Genetic variants associated with CAD and atherosclerotic disease burden are 
not associated with the severity and prognosis of patients with ischemic HF in 
the CORONA trial. Therefore, the observed secondary association of the 
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1p13.3 rs599839 G A 3,300 0.23 1,953 1,169 178 0.85 
1q41 rs17465637 A C 3,305 0.26 1,840 1,246 219 0.68 
2q36 rs2972147 T C 3,299 0.37 1,317 1,521 461 0.53 
6q25.1 rs6922269 A G 3,297 0.26 1,779 1,303 215 0.26 
9p21.3 rs1333049 C G 3,321 0.50 870 1,589 841 0.03 
10q11.21 rs501120 C T 3,300 0.15 2,425 794 81 0.11 





Supplementary Table 2. Excluded variables in adjusted analyses 
Variables in adjusted analyses 
Excluded from the 
adjusted analysis of 
Age/10   
Diabetes Mellitus   
LVEF*100 LVEF 
Sex   
Hypertension SBP 
Myocardial Infarction   
NYHA class   
Total Cholesterol 
Cholesterol, LDL, HDL, TG, apo-A1, 
Apo-B & Apo-B/Apo-A1 
Angina pectoris   
Aortic Aneurysm   
Atrial fibrillation   
BMI BMI 
CABG   
Heart rate/10 HR 
Implanted cardioverter defibrillator   
Implanted pacemaker   
Intermittent claudication   
PCI   
SBP/10 SBP 
Smoking   
Stroke   
ALAT   
CK   
TSH   
Apo-A1 
Cholesterol, LDL, HDL, TG, Apo-
A1, Apo-B and Apo-B/Apo-A1 
Apo-B 
Cholesterol, LDL, HDL, TG, Apo-
A1, Apo-B and Apo-B/Apo-A1 
Creatinine/10 Creatinine 
Triglycerides 
Cholesterol, LDL, HDL, TG, Apo-









Supplementary Table 3. CAD loci and heart failure disease markers in genetic 
sub-study of CORONA 
Variable Locus SNP Model 
LVEF 1p13.3 rs599839 Unadj. 
      Adj. 
  1q41 rs17465637 Unadj. 
      Adj. 
  2q36 rs2972147 Unadj. 
      Adj. 
  6q25.1 rs6922269 Unadj. 
      Adj. 
  9p21.3 rs1333049 Unadj. 
      Adj. 
  10q11.21 rs501120 Unadj. 
      Adj. 
  15q22.33 rs17228212 Unadj. 
      Adj. 
        
log NT-proBNP (pmol/L) 1p13.3 rs599839 Unadj. 
      Adj. 
  1q41 rs17465637 Unadj. 
      Adj. 
  2q36 rs2972147 Unadj. 
      Adj. 
  6q25.1 rs6922269 Unadj. 
      Adj. 
  9p21.3 rs1333049 Unadj. 
      Adj. 
  10q11.21 rs501120 Unadj. 
      Adj. 
  15q22.33 rs17228212 Unadj. 





Supplementary Table 3 (continued). CAD loci and heart failure disease 
markers in genetic sub-study of CORONA 
n Beta estimate Lower CI Upper CI P value 
3300 0.0002 -0.0034 0.0038 0.918 
2218 0.0012 -0.0029 0.0053 0.576 
3305 0.0003 -0.0032 0.0038 0.859 
2220 -0.0002 -0.0041 0.0037 0.919 
3299 0.0013 -0.0018 0.0044 0.42 
2216 0.001 -0.0025 0.0044 0.586 
3297 -0.0025 -0.006 0.001 0.157 
2214 -0.0031 -0.0069 0.0008 0.118 
3300 0.0044 0.0015 0.0074 0.0036 
2212 0.0038 0.0005 0.0071 0.023 
3300 0.0054 0.0012 0.0097 0.012 
2216 0.0022 -0.0025 0.0068 0.362 
3303 -0.005 -0.0084 -0.0016 0.004 
2218 -0.0031 -0.0069 0.0008 0.115 
          
2413 0.0018 -0.079 0.083 0.965 
2218 -0.006 -0.076 0.064 0.866 
2416 -0.004 -0.082 0.074 0.92 
2220 0.016 -0.05 0.082 0.634 
2407 -0.011 -0.081 0.059 0.76 
2216 0.0062 -0.053 0.065 0.838 
2407 -0.0041 -0.082 0.074 0.917 
2214 -0.03 -0.096 0.035 0.365 
2407 -0.017 -0.084 0.05 0.615 
2212 0.0007 -0.056 0.057 0.98 
2412 -0.11 -0.2 -0.012 0.027 
2216 -0.064 -0.14 0.016 0.116 
2410 0.029 -0.048 0.11 0.459 





Supplementary Table 3 (continued). CAD loci and heart failure disease 
markers in genetic sub-study of CORONA 
Variable Locus SNP Model 
BMI (kg/m2) 1p13.3 rs599839 Unadj. 
      Adj. 
  1q41 rs17465637 Unadj. 
      Adj. 
  2q36 rs2972147 Unadj. 
      Adj. 
  6q25.1 rs6922269 Unadj. 
      Adj. 
  9p21.3 rs1333049 Unadj. 
      Adj. 
  10q11.21 rs501120 Unadj. 
      Adj. 
  15q22.33 rs17228212 Unadj. 
      Adj. 
        
Serum creatinine (umol/L) 1p13.3 rs599839 Unadj. 
      Adj. 
  1q41 rs17465637 Unadj. 
      Adj. 
  2q36 rs2972147 Unadj. 
      Adj. 
  6q25.1 rs6922269 Unadj. 
      Adj. 
  9p21.3 rs1333049 Unadj. 
      Adj. 
  10q11.21 rs501120 Unadj. 
      Adj. 
  15q22.33 rs17228212 Unadj. 





Supplementary Table 3 (continued). CAD loci and heart failure disease 
markers in genetic sub-study of CORONA 
n Beta estimate Lower CI Upper CI P value 
3293 0.044 -0.21 0.3 0.736 
2218 -0.073 -0.36 0.22 0.621 
3298 0.35 0.11 0.6 0.0048 
2220 0.3 0.03 0.58 0.029 
3292 0.081 -0.14 0.3 0.473 
2216 0.23 -0.014 0.48 0.065 
3290 0.0047 -0.24 0.25 0.97 
2214 -0.11 -0.38 0.17 0.444 
3294 0.025 -0.19 0.24 0.817 
2212 0.042 -0.19 0.28 0.728 
3293 -0.11 -0.41 0.18 0.453 
2216 -0.17 -0.5 0.16 0.325 
3296 -0.15 -0.39 0.093 0.231 
2218 -0.022 -0.29 0.25 0.872 
          
3300 1.78 0.27 3.3 0.021 
2218 0.83 -0.76 2.43 0.306 
3305 -0.26 -1.72 1.2 0.729 
2220 0.081 -1.42 1.58 0.916 
3299 0.28 -1.04 1.6 0.676 
2216 0.47 -0.87 1.82 0.49 
3297 0.27 -1.2 1.74 0.714 
2214 0.76 -0.74 2.26 0.319 
3300 -0.49 -1.75 0.76 0.44 
2212 -0.32 -1.62 0.97 0.625 
3300 -2.01 -3.8 -0.21 0.028 
2216 -0.43 -2.25 1.39 0.645 
3303 1.14 -0.29 2.57 0.119 





Supplementary Table 4. CAD loci and prognosis of ischemic heart failure in 
genetic sub-study of CORONA 
Variable Locus SNP   
All-cause mortality 1p13.3 rs599839 Unadj. 
      Adj. 
  1q41 rs17465637 Unadj. 
      Adj. 
  2q36 rs2972147 Unadj. 
      Adj. 
  6q25.1 rs6922269 Unadj. 
      Adj. 
  9p21.3 rs1333049 Unadj. 
      Adj. 
  10q11.21 rs501120 Unadj. 
      Adj. 
  15q22.33 rs17228212 Unadj. 
      Adj. 
        
Mortality or WHF hospitalization 1p13.3 rs599839 Unadj. 
      Adj. 
  1q41 rs17465637 Unadj. 
      Adj. 
  2q36 rs2972147 Unadj. 
      Adj. 
  6q25.1 rs6922269 Unadj. 
      Adj. 
  9p21.3 rs1333049 Unadj. 
      Adj. 
  10q11.21 rs501120 Unadj. 
      Adj. 
  15q22.33 rs17228212 Unadj. 




Supplementary Table 4 (continued). CAD loci and prognosis of ischemic 
heart failure in genetic sub-study of CORONA 
Total n Events n Hazard ratio Lower CI Upper CI P value 
3300 527 0.862 0.744 1 0.0499 
2218 341 0.739 0.608 0.899 0.0025 
3305 530 0.934 0.813 1.074 0.3372 
2220 341 0.912 0.762 1.091 0.3124 
3299 528 1.022 0.903 1.157 0.7327 
2216 340 1.063 0.911 1.241 0.4344 
3297 524 1.017 0.886 1.167 0.814 
2214 338 1.132 0.955 1.341 0.1523 
3300 527 1.046 0.929 1.178 0.4596 
2212 339 1.04 0.896 1.207 0.6099 
3300 524 0.91 0.763 1.085 0.2939 
2216 339 0.845 0.674 1.059 0.1431 
3303 528 1.098 0.962 1.253 0.1668 
2218 340 1.042 0.879 1.234 0.6383 
            
3300 1049 0.985 0.89 1.089 0.7635 
2218 673 0.94 0.826 1.069 0.3475 
3305 1051 0.96 0.87 1.06 0.4211 
2220 672 0.949 0.836 1.077 0.4199 
3299 1052 0.94 0.86 1.027 0.1696 
2216 674 0.939 0.84 1.05 0.2715 
3297 1048 1.042 0.946 1.148 0.4002 
2214 672 1.087 0.964 1.227 0.1739 
3300 1050 0.993 0.913 1.08 0.8647 
2212 672 1.009 0.908 1.122 0.8626 
3300 1046 0.851 0.75 0.965 0.0122 
2216 670 0.82 0.699 0.962 0.0151 
3303 1052 1.063 0.967 1.17 0.2065 




Supplementary Table 5. CAD loci and hospitalizations of ischemic heart 
























Number of hospitalizations due to cardiovascular cause 
Locus SNP Ordered P value 
1p13.3 rs599839 0.064 0.0093 
1q41 rs17465637 0.356 0.489 
2q36 rs2972147 0.165 0.37 
6q25.1 rs6922269 0.258 0.194 
9p21.3 rs1333049 0.34 0.723 
10q11.21 rs501120 0.322 0.417 
15q22.33 rs17228212 0.024 0.268 
        
Number of hospitalizations due to WHF 
Locus SNP Ordered P value 
1p13.3 rs599839 0.336 0.341 
1q41 rs17465637 0.904 0.975 
2q36 rs2972147 0.056 0.058 
6q25.1 rs6922269 0.202 0.248 
9p21.3 rs1333049 0.226 0.885 
10q11.21 rs501120 0.532 0.032 






Supplementary Table 6. CAD loci and lipid characteristics in genetic sub-
study of CORONA 
Variable Locus SNP Model n 
Total Cholesterol (mmol/L) 1p13.3 rs599839 Unadj. 3285 
      Adj. 2219 
  1q41 rs17465637 Unadj. 3290 
      Adj. 2221 
  2q36 rs2972147 Unadj. 3285 
      Adj. 2217 
  6q25.1 rs6922269 Unadj. 3282 
      Adj. 2215 
  9p21.3 rs1333049 Unadj. 3285 
      Adj. 2213 
  10q11.21 rs501120 Unadj. 3285 
      Adj. 2217 
  15q22.33 rs17228212 Unadj. 3289 
      Adj. 2219 
          
LDL (mmol/L) 1p13.3 rs599839 Unadj. 3285 
      Adj. 2219 
  1q41 rs17465637 Unadj. 3290 
      Adj. 2221 
  2q36 rs2972147 Unadj. 3285 
      Adj. 2217 
  6q25.1 rs6922269 Unadj. 3282 
      Adj. 2215 
  9p21.3 rs1333049 Unadj. 3285 
      Adj. 2213 
  10q11.21 rs501120 Unadj. 3285 
      Adj. 2217 
  15q22.33 rs17228212 Unadj. 3289 
      Adj. 2219 
          
Triglycerides (mmol/L) 1p13.3 rs599839 Unadj. 3285 
      Adj. 2219 
  1q41 rs17465637 Unadj. 3290 
      Adj. 2221 
  2q36 rs2972147 Unadj. 3285 
      Adj. 2217 
  6q25.1 rs6922269 Unadj. 3282 
      Adj. 2215 
  9p21.3 rs1333049 Unadj. 3285 
      Adj. 2213 
  10q11.21 rs501120 Unadj. 3285 
      Adj. 2217 
  15q22.33 rs17228212 Unadj. 3289 





Supplementary Table 6 (continued). CAD loci and lipid characteristics in 
genetic sub-study of CORONA 
Beta estimate Lower CI Upper CI P value 
-0.14 -0.2 -0.075 1.2x10
-5
 
-0.14 -0.21 -0.07 1.1x10
-4
 
0.0089 -0.05 0.068 0.768 
0.036 -0.032 0.1 0.301 
0.0009 -0.052 0.054 0.974 
0.022 -0.039 0.084 0.478 
0.024 -0.035 0.083 0.427 
-0.015 -0.083 0.053 0.662 
-0.045 -0.095 0.0061 0.084 
-0.044 -0.1 0.015 0.145 
-0.073 -0.15 -0.001 0.047 
-0.05 -0.13 0.033 0.235 
0.028 -0.03 0.086 0.345 
0.055 -0.013 0.12 0.111 
        
-0.16 -0.22 -0.11 1.8x10
-9
 
-0.17 -0.23 -0.1 3.5x10
-7
 
-0.0008 -0.053 0.051 0.976 
0.021 -0.04 0.083 0.498 
0.024 -0.023 0.071 0.318 
0.034 -0.021 0.089 0.231 
0.023 -0.029 0.075 0.384 
-0.0059 -0.067 0.055 0.85 
-0.028 -0.073 0.016 0.212 
-0.034 -0.086 0.019 0.211 
-0.068 -0.13 -0.0044 0.036 
-0.05 -0.12 0.024 0.188 
0.017 -0.033 0.068 0.503 
0.033 -0.028 0.094 0.286 
        
0.079 0.0066 0.15 0.032 
0.074 -0.0049 0.15 0.066 
0.018 -0.052 0.088 0.619 
0.062 -0.014 0.14 0.112 
-0.12 -0.19 -0.061 1.1x10
-4
 
-0.074 -0.14 -0.0063 0.032 
-0.0056 -0.076 0.065 0.875 
-0.0089 -0.084 0.067 0.816 
-0.083 -0.14 -0.023 0.007 
-0.064 -0.13 0.0011 0.054 
-0.049 -0.14 0.036 0.259 
-0.069 -0.16 0.023 0.143 
0.017 -0.052 0.085 0.631 





Supplementary Table 6 (continued). CAD loci and lipid characteristics in 
genetic sub-study of CORONA 
Variable Locus SNP Model n 
Apo B (g/L) 1p13.3 rs599839 Unadj. 3264 
      Adj. 2218 
  1q41 rs17465637 Unadj. 3270 
      Adj. 2220 
  2q36 rs2972147 Unadj. 3265 
      Adj. 2216 
  6q25.1 rs6922269 Unadj. 3262 
      Adj. 2214 
  9p21.3 rs1333049 Unadj. 3265 
      Adj. 2212 
  10q11.21 rs501120 Unadj. 3267 
      Adj. 2216 
  15q22.33 rs17228212 Unadj. 3269 
      Adj. 2218 
          
Apo B/Apo A1 ratio 1p13.3 rs599839 Unadj. 3264 
      Adj. 2218 
  1q41 rs17465637 Unadj. 3270 
      Adj. 2220 
  2q36 rs2972147 Unadj. 3265 
      Adj. 2216 
  6q25.1 rs6922269 Unadj. 3262 
      Adj. 2214 
  9p21.3 rs1333049 Unadj. 3265 
      Adj. 2212 
  10q11.21 rs501120 Unadj. 3267 
      Adj. 2216 
  15q22.33 rs17228212 Unadj. 3269 





Supplementary Table 6 (continued). CAD loci and lipid characteristics in 
genetic sub-study of CORONA 
Beta estimate Lower CI Upper CI P value 
-0.055 -0.073 -0.038 2.2x10
-10
 
-0.056 -0.076 -0.036 5.1x10
-8
 
0.0036 -0.013 0.02 0.671 
0.01 -0.0094 0.029 0.311 
-0.0078 -0.023 0.0072 0.308 
-0.0016 -0.019 0.016 0.86 
0.0063 -0.01 0.023 0.462 
-0.005 -0.024 0.014 0.613 
-0.013 -0.027 0.0017 0.085 
-0.015 -0.032 0.0014 0.072 
-0.023 -0.043 -0.0024 0.028 
-0.021 -0.045 0.0021 0.075 
0.0037 -0.013 0.02 0.658 
0.0062 -0.013 0.026 0.527 
        
-0.047 -0.061 -0.033 3.3x10
-11
 
-0.049 -0.066 -0.032 8.0x10
-9
 
0.0032 -0.01 0.017 0.648 
0.0058 -0.01 0.022 0.48 
-0.011 -0.023 0.0016 0.089 
-0.0065 -0.021 0.0079 0.376 
-0.0007 -0.014 0.013 0.923 
-0.0082 -0.024 0.0077 0.313 
-0.011 -0.023 0.0003 0.056 
-0.017 -0.03 -0.0028 0.018 
-0.015 -0.031 0.0018 0.08 
-0.015 -0.034 0.0047 0.139 
0.0027 -0.011 0.016 0.686 
-0.005 -0.021 0.011 0.539 
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